Dr. Johnson V. John, Ph.D., Assistant Professor at the Terasaki Institute for Biomedical Innovation, has been appointed as a standing member of the NIH Musculoskeletal Tissue Engineering (MTE) Study Section. His four-year term begins in November 2025. The appointment recognizes Dr. John’s leadership in biomaterials and regenerative medicine and his ongoing contributions to advancing musculoskeletal tissue repair and engineering.

Insilico announced the launch of its innovative cardiometabolic disease portfolio at BIO Europe 2025. The portfolio covers a range of diverse mechanisms and stages from early discovery to preclinical development. It consists of eight oral small molecules with unique properties designed to unlock the full potential of established high-confidence targets such as GLP-1R, GIPR, Amylin, APJ, and Lp(a), as well as moderate-novelty targets such as NLRP3 and NR3C1.

Alcohol use disorder (AUD) affects approximately 14.1 million people in the U.S. Pharmacological treatment options for AUD have advanced only minimally since 2004, underscoring the urgent need for novel therapeutic targets. To uncover some of these potential targets, the National Institute on Alcohol Abuse and Alcoholism awarded a two-year grant to TTUHSC’s Dawei Li, Ph.D., who will seek to identify new neurobiological factors for potential intervention, including a possible link between endogenous retroviruses and neuroinflammation.

Cambridge VR, a pioneering tech startup spun out of the University of Cambridge, has been named Best Startup at the Global EdTech Awards 2025. The recognition celebrates the company’s groundbreaking virtual reality platform that provides the best treatment for speech anxiety. Multiple world-firsts have been achieved to make the platform uniquely effective and accessible.